Kennedy's rationale is based on a series of inaccuracies and part of a pattern of misrepresentation.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
A study in Israel during the Omicron variant surge finds that rates of COVID-19 infection and severe illness were lower after a fourth dose of the Pfizer/BioNTech vaccine than after three doses, and while protection against infection waned quickly after 4 weeks, protection against severe disease was still strong at 6 weeks.
Vaccination is not linked to fetal abnormalities detectable on ultrasound, study finds.
"Given the limited resources countries have, we need a new strategy."
Also, pandemic response coordinator Jeff Zients calls a $10 billion funding package only "a start."
Two new studies detail long COVID symptoms, with one from France showing that 85% of patients who had symptoms 2 months after illness onset still had them at 1 year and some symptoms worsened, and one from China revealing that 12% of patients reported rheumatic symptoms at 1-year follow-up.
In global COVID news, Shanghai's lockdown will be extended.
A new study in JAMA Pediatrics shows the Omicron variant has caused six to eight times the rate of Omicron infections in US preschoolers as the Delta variant, but cases were less severe with Omicron.
Incidence was 2 to 6 times higher after SARS-CoV-2 infection than after the second vaccine dose.
Studies in Brazil and Sweden show good efficacy against illness and hospitalization.
Three new studies to be presented at the upcoming European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) conference at the end of the month demonstrate benefits of the antiviral molnupiravir against COVID-19 infections, including evidence that Merck's pill reduces symptoms of the SARS-CoV-2 virus by day 3 of administration.
